Sweden· SE-20011214000599
Fomepizole SERB 5 mg/ml Koncentrat till infusionsvätska, lösning
A fomepizole product containing fomepizole sulfate, registered in Sweden by SERB S.A.. The same ATC class is registered in 14 of our 19 countries.
Checked against Swedish Medical Products Agency (Sweden) on
Informational only — not a medical device.
Where it is registered
Fomepizole is registered in 14 of 19 countries.
Countries holding a registration under ATC V03AB34 (fomepizole), each read from that country’s own register.
- This record: Sweden, from Swedish Medical Products Agency (Sweden)
- 7 of them publish a price we can compare per daily dose
Fomepizole · ATC V03AB34
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Finlandprice
- Franceprice
- Germany
- Icelandprice
- Ireland
- Japan
- Netherlands
- Norwayprice
- Sweden
- United Kingdom
- United Statesprice
The record
At a glance
Swedish Medical Products Agency (Sweden)- Active substance
- Fomepizole Sulfate
- Manufacturer
- SERB S.A.
- Country
- Sweden (SE)
- ATC code
- V03AB34
- ATC class
- Fomepizole
- Reimbursed
- Not published by this register
- Source register
- Swedish Medical Products Agency (Sweden)
- Last checked
- October 1, 2026
Packs & prices · 1
- se_varunummer20011214000599
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
4 interactions on record for fomepizole.
Graded by severity as the source publishes them — 4 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Fomepizole · interactions on record
4 records
- 4 severe
Most severe, free to view
- EthanolB05XX04severe
- EthanolV03AB16severe
- EthanolV03AZ01severe
- EthanolV07AB03severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Fomepizole in 6 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumFomepizole Serb 5 mg/mlSERB
- CzechiaFOMEPIZOLE SERB
- FinlandFomepizole SerbSERB S.A.
- IrelandFomepizole SERB 5 mg/mL, concentrate for solution for infusion.SERB S.A.
- NorwayFomepizole SerbSERB S.A.
- GermanyFomepizole SerbSerb Sa
Authorised across Europe · EMA
The same active substance is authorised in 11 EEA countries. Names it is sold under:
- Austria · Fomepizole Serb
- Belgium · Fomepizole Serb
- Germany · Fomepizole Serb
- Finland · Fomepizole Serb
- France · Fomepizole Serb
- Ireland · Fomepizole Serb
- Iceland · Fomepizole Serb
- Luxembourg · Fomepizole Serb
- Malta · Fomepizole Serb
- Netherlands · Fomepizole Serb
- Norway · Fomepizole Serb
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swedish Medical Products Agency (Sweden). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/b8036c92-6e8f-4c24-96e2-fbc8a89bbc33 GET /v1/drugs/b8036c92-6e8f-4c24-96e2-fbc8a89bbc33?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"source": "lakemedelsverket",
"doc_types": [
"SmPC",
"PL"
],
"se_npl_id": "20011214000599",
"product_page": "https://www.lakemedelsverket.se/sv/sok-lakemedelsfakta/lakemedel?id=20011214000599",
"product_doc_link": "https://docetp.mpa.se/LMF/Fomepizole%20SERB%20concentrate%20for%20solution%20for%20infusion%20SmPC_09001bee808319f2.pdf"
}See everything about fomepizole.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.